FY2024 Earnings Estimate for NKTR Issued By B. Riley

Nektar Therapeutics (NASDAQ:NKTR) – B. Riley issued their FY2024 earnings estimates for Nektar Therapeutics in a research note issued to investors on Tuesday, January 7th. B. Riley analyst M. Mamtani anticipates that the biopharmaceutical company will post earnings of ($0.83) per share for the year. B. Riley has a “Strong-Buy” rating on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.71) per share. B. Riley also issued estimates for Nektar Therapeutics’ Q4 2024 earnings at ($0.21) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.82) EPS, FY2026 earnings at ($0.79) EPS, FY2027 earnings at ($0.81) EPS, FY2028 earnings at ($0.76) EPS and FY2029 earnings at ($0.65) EPS.

NKTR has been the subject of a number of other reports. Piper Sandler assumed coverage on Nektar Therapeutics in a report on Monday, November 4th. They issued an “overweight” rating and a $7.00 price target for the company. HC Wainwright initiated coverage on shares of Nektar Therapeutics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $6.50 target price for the company. Finally, BTIG Research reaffirmed a “buy” rating and set a $4.00 price target on shares of Nektar Therapeutics in a research note on Monday, September 30th. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $4.08.

Nektar Therapeutics Price Performance

Shares of Nektar Therapeutics stock opened at $1.03 on Friday. Nektar Therapeutics has a 1 year low of $0.48 and a 1 year high of $1.93. The business has a 50 day moving average price of $1.09 and a 200 day moving average price of $1.21. The company has a market capitalization of $189.99 million, a P/E ratio of -1.23 and a beta of 0.59.

Insider Buying and Selling

In other Nektar Therapeutics news, CEO Howard W. Robin sold 46,995 shares of the stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $1.01, for a total transaction of $47,464.95. Following the transaction, the chief executive officer now owns 1,195,710 shares of the company’s stock, valued at $1,207,667.10. This trade represents a 3.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Mark Andrew Wilson sold 33,402 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $0.90, for a total transaction of $30,061.80. Following the sale, the insider now directly owns 351,892 shares of the company’s stock, valued at $316,702.80. This represents a 8.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 155,575 shares of company stock worth $149,878. 3.71% of the stock is owned by company insiders.

Institutional Investors Weigh In On Nektar Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Samlyn Capital LLC acquired a new position in shares of Nektar Therapeutics in the 2nd quarter valued at about $11,728,000. Eventide Asset Management LLC boosted its position in Nektar Therapeutics by 24.8% during the 3rd quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company’s stock worth $12,220,000 after purchasing an additional 1,870,904 shares during the period. Millennium Management LLC increased its holdings in Nektar Therapeutics by 56.1% in the 2nd quarter. Millennium Management LLC now owns 4,659,469 shares of the biopharmaceutical company’s stock valued at $5,778,000 after purchasing an additional 1,674,924 shares in the last quarter. Nantahala Capital Management LLC lifted its position in Nektar Therapeutics by 66.0% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,110,000 shares of the biopharmaceutical company’s stock worth $5,096,000 after acquiring an additional 1,634,046 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Nektar Therapeutics by 11.9% during the third quarter. State Street Corp now owns 3,345,733 shares of the biopharmaceutical company’s stock worth $4,349,000 after purchasing an additional 355,759 shares in the last quarter. Hedge funds and other institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.